-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
From insight database () Golimu monoantigen is a TNF-α monoantigen developed by Johnson and Johnson and Synglia, which was approved by the U.S. FDA in 2013 for the treatment of moderate to severe active rheumatoid arthritis (RA).
2019, its global sales reached $2,188 million.
December 28, 2017, Golimu Single Resistance was approved for listing in China under the name Hinpni ®, with the approved allergies to strong scolitis and rheumatoid arthritis.
2019, Golimu Single Resistance is listed in Medicare Category B and currently has a winning bid of 4,900 yuan (50mg/0.5ml/branch).
first submitted a clinical application in January 2019 and the first clinical trial in May of that year, according to the Insight database.
2020, Beotai announced an exclusive license agreement with Pharmapark to commercialize BAT2506 exclusively in Russia and other CIS countries.
company disclosed in a corporate press release that it will submit listing applications to the National Drug Administration (NMPA), the European EMA and the U.S. FDA after completing Phase 3 clinical trials.
key nodes of the BAT2506 project from the Insight database ()
